What is Bosutinib?

Bosutinibis areceptor tyrosine kinase inhibitor, used to treat patients with chronic Ph+chronic myeloid leukemia (CML) pan>'sAdult and pediatric patients aged 1 year and older, newly diagnosed or with resistance or intolerance to previous treatment and for acceleration or blast phase with resistance or intolerance to previous treatmentPh+ CMLAdult patients.

Verify pregnancy status in females of reproductive potential before initiating treatment. Monitor complete blood counts (CBC) weekly during the first month of treatment and monthly thereafter (or as clinically indicated). Monitor liver function tests monthly during the first 3 months of treatment and then as clinically indicated; more frequent monitoring is recommended if transaminase concentrations are elevated. Monitor renal function during treatment, especially in patients with preexisting renal impairment or risk factors for renal impairment. Monitor for signs and symptoms of heart failure or ischemia, fluid retention, or gastrointestinal toxicity (such as diarrhea, nausea, vomiting, abdominal pain) and treat as clinically indicated.

Bosutinib isprimarily metabolized byCYP3A4. Can inhibit breast cancer resistance protein(BRCP) in the gastrointestinal tract, has low potential for systemic inhibitionBRCP. Not likely to inhibit organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic anion transporter (OAT) at clinically relevant concentrations 1, OAT3, organic cation transporter (OCT) 1 or OCT2. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.